



May 23, 2023

To,
Listing Compliance Department
National Stock Exchange of India Limited
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Dear Madam,

**Sub: Clarification - Financial results for the quarter
and year ended March 31, 2023**

This is with reference to your e-mail dated May 23, 2023, wherein you have sought clarification regarding non-submission of Segment details in the Company's Financial results for the quarter and year ended March 31, 2023.

In this regards, kindly note that the Company deals in only one operating segment, which is based on the nature of the product, and thus the reporting segment is only one segment i.e. Pharmaceuticals. Accordingly, we had indicated the above fact while filing the financials for the year ended March 31, 2023 in XBRL form.

We request you to take the above clarification on your record.

Thanking you,

Yours faithfully,
For **AARTI PHARMALABS LIMITED**
(Formerly known as Aarti Organics Limited)

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655